Author

Holly Baldock

Observed names: Baldock, Holly, H. Baldock

Institutions: Mayo Clinic, Institute of Cancer Research, Institute of Cancer Research, Imperial College London

Observed institutions: Mayo Clinic, Institute of Cancer Research, Institute of Cancer Research, Imperial College London

ORCID: 0000-0003-2751-4549

Observed ORCID: 0000-0003-2751-4549

OpenAlex ID: A5048520208

A RIPK1-specific PROTAC degrader achieves potent antitumor activity by enhancing immunogenic cell death

2024 · Jonathan Mannion, Valentina Gifford, et al. · Immunity · 93

Harnessing radiotherapy-induced NK-cell activity by combining DNA damage–response inhibition and immune checkpoint blockade

2022 · Emmanuel C Patin, Magnus T Dillon, et al. · Journal for ImmunoTherapy of Cancer · 74

Sculpting the tumour microenvironment by combining radiotherapy and ATR inhibition for curative-intent adjuvant immunotherapy

2024 · Emmanuel C. Patin, Pablo Nenclares, et al. · Nature Communications · 21

Effects of oncolytic immunotherapy with RP1 (vusolimogene oderparepvec) on immune cells mediate responsiveness to anti-PD-1 via STING-mediated interferon signaling

2026 · Victoria Roulstone, Joan Kyula, et al. · Journal for ImmunoTherapy of Cancer · 5

Palbociclib and dsRNA sensor co-operate to enhance anti-cancer effects through ER stress and modulation of immune evasion

2025 · Victoria Roulstone, Joan Kyula-Currie, et al. · Nature Communications · 5

Xevinapant plus Chemoradiotherapy Negatively Sculpts the Tumor-Immune Microenvironment in Head and Neck Cancer

2025 · Charleen Chan Wah Hak, Emmanuel C. Patin, et al. · Cancer Research Communications · 3

Author Correction: Palbociclib and dsRNA sensor co-operate to enhance anti-cancer effects through ER stress and modulation of immune evasion

2025 · Victoria Roulstone, Joan Kyula-Currie, et al. · Nature Communications · 1

Preclinical efficacy of a systemically-administered, second-generation STING agonist that promotes anti-tumour immunity in combination with radiotherapy

2026 · Malin Pedersen, Lisa C. Hubbard, et al. · British Journal of Cancer

Addition of chemotherapy to radiotherapy promotes progenitor-exhausted CD8⁺ T-cell clonal dominance in head and neck cancer

2026 · Charleen Chan Wah Hak, Anton Patrikeev, et al. · Cancer Immunology Research

Addition of chemotherapy to radiotherapy promotes progenitor-exhausted CD8⁺ T-cell clonal dominance in head and neck cancer

2026 · Chan Wah Hak, Charleen, Patrikeev, Anton, et al. · UCL Discovery (University College London)

Intratumoural oncolytic HSV-1 reshapes the local and systemic immune landscape through CD8 ⁺ T cell reprogramming

2026 · Elizabeth Appleton, Anton Patrikeev, et al. · bioRxiv (Cold Spring Harbor Laboratory)

Preclinical efficacy of a systemically-administered, second-generation STING agonist that promotes antitumour immunity in combination with radiotherapy

2026 · Malin Pedersen, Lisa Hubbard, et al. · bioRxiv (Cold Spring Harbor Laboratory)

Addition of chemotherapy to radiotherapy promotes progenitor-exhausted CD8⁺ T-cell clonal dominance in head and neck cancer

2026 · Charleen Chan Wah Hak, Anton Patrikeev, et al. · bioRxiv (Cold Spring Harbor Laboratory)

Data from Xevinapant plus Chemoradiotherapy Negatively Sculpts the Tumor-Immune Microenvironment in Head and Neck Cancer

2025 · Charleen Chan Wah Hak, Emmanuel C. Patin, et al.

Figure 3 from Xevinapant plus Chemoradiotherapy Negatively Sculpts the Tumor-Immune Microenvironment in Head and Neck Cancer

2025 · Charleen Chan Wah Hak, Emmanuel C. Patin, et al.

Figure S1 from Xevinapant plus Chemoradiotherapy Negatively Sculpts the Tumor-Immune Microenvironment in Head and Neck Cancer

2025 · Charleen Chan Wah Hak, Emmanuel C. Patin, et al.

Figure 1 from Xevinapant plus Chemoradiotherapy Negatively Sculpts the Tumor-Immune Microenvironment in Head and Neck Cancer

2025 · Charleen Chan Wah Hak, Emmanuel C. Patin, et al.

Figure S5 from Xevinapant plus Chemoradiotherapy Negatively Sculpts the Tumor-Immune Microenvironment in Head and Neck Cancer

2025 · Charleen Chan Wah Hak, Emmanuel C. Patin, et al.

Figure S6 from Xevinapant plus Chemoradiotherapy Negatively Sculpts the Tumor-Immune Microenvironment in Head and Neck Cancer

2025 · Charleen Chan Wah Hak, Emmanuel C. Patin, et al.

Figure S4 from Xevinapant plus Chemoradiotherapy Negatively Sculpts the Tumor-Immune Microenvironment in Head and Neck Cancer

2025 · Charleen Chan Wah Hak, Emmanuel C. Patin, et al.

Figure 2 from Xevinapant plus Chemoradiotherapy Negatively Sculpts the Tumor-Immune Microenvironment in Head and Neck Cancer

2025 · Charleen Chan Wah Hak, Emmanuel C. Patin, et al.

Figure 4 from Xevinapant plus Chemoradiotherapy Negatively Sculpts the Tumor-Immune Microenvironment in Head and Neck Cancer

2025 · Charleen Chan Wah Hak, Emmanuel C. Patin, et al.

Supplementary Data from Xevinapant plus Chemoradiotherapy Negatively Sculpts the Tumor-Immune Microenvironment in Head and Neck Cancer

2025 · Charleen Chan Wah Hak, Emmanuel C. Patin, et al.

Figure S7 from Xevinapant plus Chemoradiotherapy Negatively Sculpts the Tumor-Immune Microenvironment in Head and Neck Cancer

2025 · Charleen Chan Wah Hak, Emmanuel C. Patin, et al.

Figure S3 from Xevinapant plus Chemoradiotherapy Negatively Sculpts the Tumor-Immune Microenvironment in Head and Neck Cancer

2025 · Charleen Chan Wah Hak, Emmanuel C. Patin, et al.

Works count: 29

Citation count: 202

H-index: 5

I10-index: 3